JP6072201B1 - アセチルコリンエステラーゼ阻害剤及びその用途 - Google Patents
アセチルコリンエステラーゼ阻害剤及びその用途 Download PDFInfo
- Publication number
- JP6072201B1 JP6072201B1 JP2015223954A JP2015223954A JP6072201B1 JP 6072201 B1 JP6072201 B1 JP 6072201B1 JP 2015223954 A JP2015223954 A JP 2015223954A JP 2015223954 A JP2015223954 A JP 2015223954A JP 6072201 B1 JP6072201 B1 JP 6072201B1
- Authority
- JP
- Japan
- Prior art keywords
- ache
- cryptomellidiol
- abietatriene
- hibaen
- acetylcholinesterase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title claims abstract description 15
- GXMKKDDGINQVBE-UHFFFAOYSA-N hibaene Chemical compound C1CC2C(C)(C)CCCC2(C)C2C1(C=C1)CC1(C)CC2 GXMKKDDGINQVBE-UHFFFAOYSA-N 0.000 claims abstract description 31
- HDNRAPAFJLXKBV-UHFFFAOYSA-N 1-ethyl-4-methoxybenzene Chemical compound CCC1=CC=C(OC)C=C1 HDNRAPAFJLXKBV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 206010039966 Senile dementia Diseases 0.000 claims description 7
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- LKKDASYGWYYFIK-JURCDPSOSA-N (+)-4-epi-cryptomeridiol Chemical compound C1CC[C@](C)(O)[C@H]2C[C@@H](C(C)(O)C)CC[C@@]21C LKKDASYGWYYFIK-JURCDPSOSA-N 0.000 claims description 3
- LKKDASYGWYYFIK-UHFFFAOYSA-N (-)-cryptomeridiol Natural products C1CCC(C)(O)C2CC(C(C)(O)C)CCC21C LKKDASYGWYYFIK-UHFFFAOYSA-N 0.000 claims description 3
- PYDYAPFBFDTVMM-UHFFFAOYSA-N Cryptomeridiol Natural products C1CCC(O)C2CC(C(C)(O)C)CCC21C PYDYAPFBFDTVMM-UHFFFAOYSA-N 0.000 claims description 3
- 230000005978 brain dysfunction Effects 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 abstract description 23
- -1 13-epi-drabradiene Chemical compound 0.000 abstract description 19
- QUUCYKKMFLJLFS-UHFFFAOYSA-N Dehydroabietan Natural products CC1(C)CCCC2(C)C3=CC=C(C(C)C)C=C3CCC21 QUUCYKKMFLJLFS-UHFFFAOYSA-N 0.000 abstract description 18
- QUUCYKKMFLJLFS-AZUAARDMSA-N abietatriene Chemical compound CC1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 QUUCYKKMFLJLFS-AZUAARDMSA-N 0.000 abstract description 18
- 229940124596 AChE inhibitor Drugs 0.000 abstract description 12
- FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 abstract description 9
- FQTLCLSUCSAZDY-SZGZABIGSA-N (E)-Nerolidol Natural products CC(C)=CCC\C(C)=C/CC[C@@](C)(O)C=C FQTLCLSUCSAZDY-SZGZABIGSA-N 0.000 abstract description 9
- FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 abstract description 9
- 102100033639 Acetylcholinesterase Human genes 0.000 description 29
- 108010022752 Acetylcholinesterase Proteins 0.000 description 29
- 230000002401 inhibitory effect Effects 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 241000196324 Embryophyta Species 0.000 description 13
- 241000218645 Cedrus Species 0.000 description 9
- 241000218691 Cupressaceae Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 6
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
- 238000000222 aromatherapy Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000000605 extraction Methods 0.000 description 4
- NIEHEMAZEULEKB-UHFFFAOYSA-N ortho-ethylanisole Natural products CCC1=CC=CC=C1OC NIEHEMAZEULEKB-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229940022698 acetylcholinesterase Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000003965 capillary gas chromatography Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- ODFCWXVQZAQDSO-CMKODMSKSA-N (2s,4as,10ar)-1,1,4a-trimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-2,6-diol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)C1=C2C=C(C(C)C)C(O)=C1 ODFCWXVQZAQDSO-CMKODMSKSA-N 0.000 description 1
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
エチルアニソール及び(E)−ネロリドールは、いずれも東京化成工業株式会社製のものを使用した。
AChE阻害活性試験は、Bruehmannらによって以前報告された96ウェルのマイクロプレート法(Bruehmann, C.; Marston, A.; Hostettmann, K.; Carrupt, P-A.; Testa, B. Screening of Non-Alkaloidal Natural Compounds as Acetylcholinesterase Inhibitors. Chem. Biodiver. 2004, 1, 819-829)を改良した方法で行った。以下、簡単に説明する。ウェルに20μlのAChE溶液(0.01Mリン酸緩衝液中に0.037unit/mL、pH7.4)、200μlの発色剤(5,5’−ジチオビス(2−ニトロベンゾイックアシッド;DTNB)(0.1Mリン酸緩衝液中に0.15mM、pH7.4)、及び20μlの阻害剤(表1に記載の化合物)メタノール溶液を添加した。コントロールウェルには、阻害剤の代わりにメタノールを加えた。各ウェル中の内容物を混合し、室温で、15分間プレインキュベーションした後、30μlの基質(アセチルチオコリン アイオダイド;ATC)水溶液(最終濃度:0.05−0.25mM)を加え、15分間インキュベーションした。その後、AChEによる基質の加水分解反応により生じる黄色に呈色するアニオン(TNB)の405nmにおける吸光度を、マイクロプレートリーダを用いて測定した。AChE活性の阻害(パーセント)は式:
I(%)={(Aコントロール−A試料)/Aコントロール}×100
(式中、「A試料」は試料(阻害剤)を含む反応混合物の吸光度であり、「Aコントロール」は反応コントロール混合物の吸光度を示す)を用いて計算した。なお、(+)−プレゴンはポジティブコントロールとして用いた。各サンプルについて少なくとも3回測定を行い、その平均値を示した。その結果を表1及び図2に示す。
アビエタトリエン、クリプトメリジオール、及びヒバエンの酵素阻害形式を検討した。方法は、速度論法に汎用される、Dixon plot法を用いた。Dixon plot法は、基質濃度を固定し、阻害剤濃度に対し反応速度の逆数をプロットするものである。アビエタトリエンの結果を図3に、クリプトメリジオールの結果を図4に、ヒバエンの結果を図5に示す。図3〜図5の結果は、それぞれの基質濃度に対するDixonプロットが第2象限において交差したことから、アビエタトリエン、クリプトメリジオール、及びヒバエンはいずれも拮抗阻害剤であることを示した。
Claims (5)
- 4−エチルアニソール、クリプトメリジオール、イソピマラ−9(11)9,15−ジエン、ヒバエン、及び13−epi−ドラブラジエンからなる群から選択される少なくとも1種を有効成分として含有するアセチルコリンエステラーゼ阻害剤。
- ヒバエン、及びクリプトメリジオールからなる群から選択される少なくとも1種を有効成分として含有する、請求項1に記載のアセチルコリンエステラーゼ阻害剤。
- 請求項1又は2に記載のアセチルコリンエステラーゼ阻害剤を含有する老人性痴呆症の治療又は予防薬。
- 請求項1又は2に記載のアセチルコリンエステラーゼ阻害剤を含有する脳機能障害改善薬。
- 請求項1又は2に記載のアセチルコリンエステラーゼ阻害剤を含有するアルツハイマー型痴呆症の治療又は予防薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015223954A JP6072201B1 (ja) | 2015-11-16 | 2015-11-16 | アセチルコリンエステラーゼ阻害剤及びその用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015223954A JP6072201B1 (ja) | 2015-11-16 | 2015-11-16 | アセチルコリンエステラーゼ阻害剤及びその用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6072201B1 true JP6072201B1 (ja) | 2017-02-01 |
JP2017088578A JP2017088578A (ja) | 2017-05-25 |
Family
ID=57937482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015223954A Active JP6072201B1 (ja) | 2015-11-16 | 2015-11-16 | アセチルコリンエステラーゼ阻害剤及びその用途 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6072201B1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005272421A (ja) * | 2004-03-26 | 2005-10-06 | Earth Studio Co Ltd | アセチルコリンエステラーゼ阻害剤 |
JP2006131589A (ja) * | 2004-11-09 | 2006-05-25 | Univ Kinki | アセチルコリンエステラーゼ阻害剤 |
JP2011068597A (ja) * | 2009-09-25 | 2011-04-07 | Picaso Cosmetic Laboratory Ltd | アセチルコリンエステラーゼ阻害剤 |
-
2015
- 2015-11-16 JP JP2015223954A patent/JP6072201B1/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005272421A (ja) * | 2004-03-26 | 2005-10-06 | Earth Studio Co Ltd | アセチルコリンエステラーゼ阻害剤 |
JP2006131589A (ja) * | 2004-11-09 | 2006-05-25 | Univ Kinki | アセチルコリンエステラーゼ阻害剤 |
JP2011068597A (ja) * | 2009-09-25 | 2011-04-07 | Picaso Cosmetic Laboratory Ltd | アセチルコリンエステラーゼ阻害剤 |
Non-Patent Citations (6)
Title |
---|
JPN6016034592; RJPBCS Vol.4, Issue 2, 2013, p.1419-1428 * |
JPN6016034593; Natural Product Research Vol.29, No.3, 201501, p.213-222 * |
JPN6016034594; Food and Chemical Toxicology Vol.59, 2013, p.586-594 * |
JPN6016034595; 富山県薬事研究所年報 No.21, 1994, p.29-35 * |
JPN6016034596; Rec.Nat.Prod. Vol.6, No.1, 2012, p.35-48 * |
JPN6016034597; Natural Product Communications Vol.4, No.9, 2009, p.1271-1276 * |
Also Published As
Publication number | Publication date |
---|---|
JP2017088578A (ja) | 2017-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bağdat et al. | The essential oil of lemon balm (Melissa officinalis L.), its components and using fields | |
EP1346726A1 (en) | Sympathetic-activating perfume composition | |
KR101260371B1 (ko) | 뽕나무 추출물을 포함하는 항균 탈취 조성물 | |
EP2554177A1 (en) | Expression modulator for clock gene bmal | |
Asgarpanah et al. | An overview on phytopharmacology of Pelargonium graveolens L. | |
JP6412901B2 (ja) | 組成物の製造方法 | |
EP3116520A1 (en) | Phytocomplexes from citrus bergamia | |
KR20150104916A (ko) | 칡의 꽃으로부터 추출된 정유를 포함하는 피부 재생용 외용제 및 화장료 조성물 | |
AU2022201271A1 (en) | Honokiol and Magnolol Formulations with Increased Stability and Improved Uptake, and Methods of Use Thereof | |
Khan et al. | Lavender plant: farming and health benefits | |
JP5467795B2 (ja) | β−セクレターゼ阻害剤 | |
JP4878748B2 (ja) | アセチルコリンエステラーゼ阻害剤 | |
JP2011168555A (ja) | 鑑別方法 | |
KR20180051822A (ko) | 지칭개꽃으로부터 추출된 정유를 포함하는 피부재생용 조성물 | |
EP1932532A1 (en) | Dieting composition comprising plant-derived essential oil as active ingredient, sheet-type dieting composition comprising the composition, transdermal pharmaceutical preparation for dieting, and methods for production of the preparation | |
JP5013659B2 (ja) | アセチルコリンエステラーゼ阻害剤 | |
JP6072201B1 (ja) | アセチルコリンエステラーゼ阻害剤及びその用途 | |
KR101685773B1 (ko) | 산국 에센셜 오일을 유효성분으로 함유하는 항산화 및 항비만 조성물 | |
KR101729920B1 (ko) | 천연 정유 및 천연 하이드로졸을 포함하는 아로마테라피 세럼 조성물 | |
McLain | Chronic Health Effects Assessment of Spike Lavender Oil | |
JP2016079125A (ja) | β−セクレターゼ阻害剤及びアセチルコリンエステラーゼ阻害剤 | |
JP5578822B2 (ja) | アセチルコリンエステラーゼ阻害剤 | |
JPH06340542A (ja) | 薬用植物由来の骨疾患の予防・治療剤 | |
JP7436975B2 (ja) | 精油組成物 | |
KR102329522B1 (ko) | 골담초 꽃 오일을 포함하는 피부 재생 또는 주름개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161107 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161227 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6072201 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |